We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SGMT

Price
8.72
Stock movement up
+0.17 (2.37%)
Company name
Sagimet Biosciences Inc. Series A Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
227.86M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
160.64%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-09-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

SGMT does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open7.03
Daily high7.40
Daily low7.02
Daily Volume381K
All-time high18.42
1y analyst estimate23.44
Beta3.41
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date12 Nov 2025

Downside potential

Loading...
Downside potential data
SGMTS&P500
Current price drop from All-time high-60.10%-1.46%
Highest price drop-89.69%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-66.42%-10.99%
Avg time to new high76 days12 days
Max time to new high398 days1805 days
COMPANY DETAILS
SGMT (Sagimet Biosciences Inc. Series A Common Stock) company logo
Marketcap
227.86M
Marketcap category
Small-cap
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Employees
14
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...